Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.

被引：0
|
作者：
Xu, Yongkang [1 ]
Fu, Shumin [1 ]
Mao, Ye [1 ]
Yi, Fengming [1 ]
Jiang, Weiming [1 ]
Feng, Long [1 ]
Wu, Jianbing [1 ]
机构：
[1] Nanchang Univ, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
298-145-222-184-4809-5347; 281-5277-2622-5397; 281-5277-6771; 261-492-2769; 3282-3306-3348-4026; 283-2494; 613-135-244-3829-325; 3; 2; 28; 2424; 54; 239; 193; 1700; 4; 1; 38092-32104; 38116-38094-8;
D O I：
10.1200/JCO.2024.42.3_suppl.500
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：500 / 500
页数：1
相关论文
共 50 条
  • [21] Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma
    Yang, Jing
    Shang, Xianfu
    Li, Junbiao
    Wei, Ning
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (01) : 346 - 355
  • [22] The safety and efficacy of adebelimumab combined apatinib and hepatic artery infusion chemotherapy in the treatment of unresectable hepatocellular carcinoma: A retrospective study.
    Chen, Bin
    Lin, Run
    Huang, Yonghui
    Dai, Haitao
    Tang, Keyu
    Zhang, Guiyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study
    Chen, Ruiqing
    Li, Lingbing
    Li, Ye
    Song, Ke
    Shen, Chenyu
    Ma, Pengkai
    Wang, Zhijun
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (03) : 1367 - 1375
  • [24] Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
    Zhao, Rongce
    Zhou, Jing
    Li, Shaohua
    Wei, Wei
    Guo, Rongping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
    Zhao, Rongce
    Zhou, Jing
    Miao, Zhaoxia
    Xiong, Xinhao
    Wei, Wei
    Li, Shaohua
    Guo, Rongping
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [26] Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma: An open-label, single-arm, phase 2 study-The CISLD-12 study.
    Liang, Tingbo
    Chen, Yiwen
    Huang, Xin
    Hu, Wendi
    Li, Xiang
    Sun, Junhui
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Yu, Jun
    Que, Risheng
    Zhang, Yun
    Yang, Fuchun
    Xia, Weiliang
    Zhang, Aibin
    Tang, Xiaofeng
    Bai, Xueli
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 558 - 558
  • [27] HILL: The efficacy and safety of hepatic arterial infusion chemotherapy with FOLFOX regimen combine lenvatinib and durvalumab in unresectable hepatocellular carcinoma: A prospective, phase II, single-armed, clinical trial
    Li, S.
    Lu, L.
    Wang, Q.
    Zhao, R.
    Mei, J.
    Li, J-B.
    Zheng, L.
    Wei, W.
    Guo, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S670 - S671
  • [28] Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
    Shao, Guoliang
    Zeng, Hui
    Zhang, Zhewei
    Luo, Jun
    Zhang, Dinghu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 499 - 499
  • [29] Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor for treating unresectable hepatocellular carcinoma
    Bai, Zhenhua
    Yu, Xianhuan
    Tang, Qibin
    Zhang, Rui
    Shi, Xiangde
    Liu, Chao
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2024, 85 (07)
  • [30] Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma
    Yuan, Wei
    Yue, Wenchao
    Wen, Huabing
    Wang, Xueqin
    Wang, Qi
    EUROPEAN SURGICAL RESEARCH, 2023, 64 (02) : 268 - 277
12345